医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ResMed to Report Third Quarter Fiscal 2019 Earnings on May 2, 2019

2019年04月12日 AM05:05
このエントリーをはてなブックマークに追加


 

SAN DIEGO

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.

Earnings webcast details:

       

  Location:      

http://investor.resmed.com

Date: Thursday, May 2, 2019

Time: 1:30 p.m. PT / 4:30 p.m. ET

International: London, Thursday, May 2, 9:30 p.m.
Sydney, Friday, May 3, 6:30 a.m.
 

Please note that ResMed does not use outside phone lines to access the earnings call.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from May 2 until May 16 at:

       

  U.S.:       +1 800.585.8367

International: +1 416.621.4642

Passcode: 3977963
 

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190411005679/en/

CONTACT

For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com

For investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease